$37.740
+1.008 (+2.67%)收盤時
PNTG 營收結構
The Pennant Group, Inc. (PNTG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medicare, accounting for 50.9% of total sales, equivalent to $151.65M. Other significant revenue streams include Private and other and Medicaid. Understanding this composition is critical for investors evaluating how PNTG navigates market cycles within the Healthcare Facilities & Services industry.
PNTG 獲利能力與利潤率
Evaluating the bottom line, The Pennant Group, Inc. maintains a gross margin of 12.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.22%, while the net margin is 3.66%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PNTG converts its operational activities into shareholder value.
PNTG 同業比較
In the context of the broader market, PNTG competes directly with industry leaders such as NUTX and GDRX. With a market capitalization of $1.28B, it holds a leading position in the sector. When comparing efficiency, PNTG's gross margin of 12.91% stands against NUTX's 67.04% and GDRX's 78.41%. Such benchmarking helps identify whether The Pennant Group, Inc. is trading at a premium or discount relative to its financial performance.
Pennant Group Inc 財務表現
Pennant Group has demonstrated consistent revenue growth, with Q2 2026 revenue of $298 million, up from $219 million in Q2 2025. The net income for Q2 2026 was $9.08 million, reflecting a healthy net margin of 3.66%.
Financials
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。